Last updated: June 13, 2026
VISIPAQUE 270 suppliers: Who manufactures and supplies the iopamidol contrast product (270 mgI/mL)?
Executive summary: VISIPAQUE 270 is an iopamidol injection (270 mg iodine/mL) marketed in the US by GE HealthCare (formerly GE Healthcare). The iopamidol active substance and finished-dose supply chain typically involves (1) a core chemical producer for iopamidol and (2) GE HealthCare’s finished-goods manufacture and distribution for the US label. Public-facing supplier visibility is limited because GE HealthCare sells the branded finished drug and does not consistently publish upstream API or secondary manufacturing-partner names on labeling or in public product brochures.
Who are the manufacturing and supply partners for VISIPAQUE 270 iopamidol injection?
Answer (market structure):
VISIPAQUE 270 is supplied as a finished sterile radiographic contrast product under a branded US label, with GE HealthCare as the marketer/holder of record. Upstream supplier names for iopamidol API and contract manufacturing for the finished sterile dosage are not consistently disclosed in US labeling.
What does VISIPAQUE 270 labeling typically disclose about manufacturing?
- US prescribing information generally identifies the manufacturer(s) of record and the labeler/distributor on the carton and PI.
- Those entries typically name the finished-dose manufacturing site(s), not necessarily the upstream iopamidol API supplier.
- Supplier disclosure tends to change across lifecycle events such as site transfers, contract manufacturing updates, and packaging refreshes.
Supply chain interpretation used in procurement and diligence
For contrast media, procurement teams usually segment suppliers into:
- Finished-dose manufacturer (sterile, filled, packaged product under the brand)
- API supplier (iopamidol raw material, multiple possible sources)
- Packaging/secondary labeling contractor (cartoning, labeling, distribution logistics)
- Medical device/closure component suppliers (syringe or vial components depending on presentation)
Public sources more reliably show #1 than #2.
Is GE HealthCare the supplier of record for VISIPAQUE 270?
Answer: Yes. GE HealthCare is the branded marketer/distributor and the practical supplier of VISIPAQUE 270 in US commercial channels (label holder and sales organization). In purchasing terms, GE HealthCare is the direct commercial supply point for the branded product, subject to distributor arrangements used by wholesalers.
How to treat “supplier” in RFPs for VISIPAQUE 270
In tender documents, “supplier” usually maps to one of:
- Contracted vendor (GE HealthCare or a contracted distributor)
- Manufacturer of record (site name on the label)
- Authorized distributor list entry
For cross-border contracting, the manufacturer of record and local distributor may differ by country.
What companies supply iopamidol API used to make VISIPAQUE 270?
Answer: iopamidol API suppliers exist globally, but specific API supplier names for VISIPAQUE 270 are not reliably stated in public US product labeling.
Why API supplier identification is hard for branded contrast agents
- Contrast agent API is often sourced through qualification programs and NDA-backed supplier agreements.
- GE HealthCare may buy iopamidol from more than one API manufacturer for supply resilience.
- Finished-dose contracts can shift between GMP sites without changing the marketed brand entity.
Procurement practice: how buyers confirm API provenance
High-stakes buyers typically require:
- GMP certificates for the finished-dose manufacturer
- DMF/ASMF references in regulatory submissions (where available)
- Certificate of analysis (CoA) traceability and batch-level vendor confirmation
Those data are usually available through the supplier quality agreement rather than public web listings.
Which manufacturing sites produce VISIPAQUE 270 injection in the US?
Answer: VISIPAQUE 270 is manufactured at manufacturer(s) named in the US prescribing information and product labeling. Those site names can change over time due to manufacturing transfers.
What to check in diligence packages
- Latest prescribing information “Manufactured for/Distributed by” sections
- Labeler name and address on the carton
- NDC label and package insert for the presentation size and form (vials/syringes)
What presentations of VISIPAQUE 270 exist, and do they use the same suppliers?
Answer: VISIPAQUE 270 commonly appears in multiple container formats (for example vial and prefilled syringe formats depending on region). Supplier of record is usually the same, but fill-finish and packaging can be handled at different sites for different presentations.
Supplier implications by container
- Vials: often filled in bulk or dedicated fill lines; packaging contract can differ.
- Prefilled syringes: typically require additional subassembly streams (syringe components, plunger types, sterile assembly).
Procurement and pharmacovigilance programs typically treat container format as a separate supply-risk profile.
What is the regulatory status of VISIPAQUE 270 (FDA) that affects supplier visibility?
Answer: VISIPAQUE 270 is an FDA-approved prescription radiographic contrast agent. Approval as a branded product generally limits public detail on upstream API sources compared with generic products.
Key regulatory documents that drive supplier mapping
- FDA-approved prescribing information
- CMC sections in regulatory submissions (not fully public)
- In some cases, publicly accessible FDA correspondence or data tied to supplement approvals
Which suppliers are likely on the packaging and distribution side for VISIPAQUE 270?
Answer: Distribution is typically handled through GE HealthCare’s US distribution organization and/or authorized wholesalers. Packaging and secondary labeling can be performed by:
- The same GMP manufacturer
- A specialized packaging contractor
- A regional distribution center network
The direct names of packaging contractors are rarely stated in public label text.
How many different supplier sources are used for VISIPAQUE 270 to manage shortages?
Answer: Branded sterile injectable products often maintain a multi-source strategy for raw material and at least partial redundancy for fill-finish capacity. The exact number of qualified API and sterile manufacturing sites is not consistently published.
What matters in shortage-risk analysis
- Single-site manufacturing dependence (finished dose)
- API supply concentration (iopamidol concentration)
- Sterility testing and release capacity constraints
- Component constraints for syringe/vial closures
Key Takeaways
- GE HealthCare is the practical supplier/brand marketer for VISIPAQUE 270 in the US channel.
- US labeling more reliably identifies finished-dose manufacturer(s) than upstream iopamidol API suppliers.
- For supplier due diligence, procurement should focus on manufacturer of record on the package insert, batch traceability, and quality documentation, since upstream iopamidol source names are typically not public.
FAQs
1) Who sells VISIPAQUE 270 in the US market?
GE HealthCare is the branded sales/distribution entity for VISIPAQUE 270, with commercial fulfillment typically routed through authorized distributors/wholesalers.
2) Are iopamidol API suppliers listed on VISIPAQUE 270 labeling?
Not reliably. US labeling typically focuses on the branded product manufacturer of record and does not consistently publish upstream API supplier identities.
3) Do vial and prefilled syringe versions of VISIPAQUE 270 come from the same manufacturing site?
Often the same brand supply chain, but fill-finish and packaging can differ by presentation and can be handled at different GMP sites.
4) How do hospitals verify the supplier and manufacturing site for a VISIPAQUE 270 batch?
Through the lot-level documentation provided by the supplier, including CoA, labeler/manufacturer of record details printed on the carton, and traceability under the hospital’s vendor quality agreement.
5) Does FDA approval for VISIPAQUE 270 reveal the contract manufacturing partners?
FDA approval provides the product status, but contract manufacturing and upstream API partner details are usually not fully exposed in public label text.
References (APA)
- Food and Drug Administration. (n.d.). Drugs@FDA: VISIPAQUE 270. FDA.
- GE HealthCare. (n.d.). VISIPAQUE (iopamidol) prescribing information.
